Olanzapine Hydrochloride
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jun 1, 2004 → Nov 1, 2004
NCT ID
NCT00485810About Olanzapine Hydrochloride
Olanzapine Hydrochloride is a phase 1/2 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00485810. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00485810 | Phase 1/2 | Completed |
| NCT00485823 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia